# Clinical ink

> Clinical ink supplies clinical trial data capture software and supporting services to sponsors, CROs, and research teams. Its eSource approach records data at the patient encounter, while its broader portfolio combines electronic assessments, consent, connected devices, cognitive testing, and patient adherence tools.

- **Founded:** 2007
- **Headquarters:** Winston-Salem, United States
- **Founders:** Doug Pierce (Co-founder; former president), Tommy Littlejohn (Co-founder; former president)
- **Products:** Direct Data Capture / eSource, EDCXtra, eCOA / ePRO, eConsent and Televisit, Digital biomarkers and cognitive assessments
- **Notable:** 2014 Clinical Informatics News Best Practices Award in Study Startup and Design., Reported 16 concurrent Phase II/III Alzheimer’s studies, supporting more than 9,000 patients across 25 countries, in April 2021., Expanded cognitive, behavioral, and sensor capabilities through the 2021 Digital Artefacts acquisition.

## Products & services

- **Direct Data Capture / eSource** — Electronic source records captured during patient encounters, with immediate validation and remote review.
- **EDCXtra** — Web-based EDC, DDC, eCOA, and eConsent supporting direct entry and paper transcription workflows.
- **eCOA / ePRO** — Electronic clinical outcome assessments and patient diaries for site and remote use.
- **eConsent and Televisit** — Electronic consent and telehealth capabilities for study participation.
- **Digital biomarkers and cognitive assessments** — Active assessments and sensor-based measurements, expanded through Digital Artefacts.
- **GlucoseReady** — Combines glucose monitoring, electronic assessments, and connected-device data for cardiometabolic research.
- **SPUR** — Behavioral assessment and personalized adherence support; US cardiometabolic care rights licensed from Observia.
- **Kaitality** — Announced app pairing adherence support with weight, body-composition, and activity measurements for obesity therapies.

## Achievements

- 2014 Clinical Informatics News Best Practices Award in Study Startup and Design.
- Reported 16 concurrent Phase II/III Alzheimer’s studies, supporting more than 9,000 patients across 25 countries, in April 2021.
- Expanded cognitive, behavioral, and sensor capabilities through the 2021 Digital Artefacts acquisition.

## Latest updates

- **2026-04** — Announced Kaitality and a Disease Management business unit; observational studies planned before wider patient-support and payer use.
- **2026-01** — Announced US cardiometabolic care license for Observia’s SPUR adherence solution.
- **2025-12** — Announced automated insulin delivery integration with Tandem Diabetes Care.

## Links

- Website: https://www.clinicalink.com/
- LinkedIn: https://www.linkedin.com/company/clinical-ink/
- Twitter/X: https://twitter.com/ClinicalInk
- YouTube: https://www.youtube.com/@ClinicalInk1
- Facebook: https://facebook.com/ClinicalInk1/

---

Profile page: https://yespress.io/clinical-ink
Published by YesPress — https://yespress.io
Last updated: 2026-10-01